15 October2026: SYS6062 ADC received clinical trial approval in China
CSPC Pharmaceutical Group announced that SYS6062, its investigational antibody-drug conjugate, has received approval from China’s National Medical Products Administration to initiate clinical trials in patients with advanced solid tumors. The candidate was filed as a Class 1 therapeutic biological product
The clinical trial approval follows preclinical studies demonstrating antitumor activity against multiple cancer types
The program addresses the unmet need for effective treatments for advanced solid tumors, where patients may have limited therapeutic options following disease progression or resistance to existing treatments. SYS6062’s entry into clinical development provides an opportunity to evaluate a targeted drug-delivery approach across solid tumor indications
SYS6062 is a monoclonal antibody-drug conjugate designed to bind specific receptors on tumor cell surfaces, undergo receptor-mediated internalization through endocytosis, and release a cytotoxic payload intracellularly to kill tumor cells
Strategically, the NMPA clinical trial approval expands CSPC’s oncology development pipeline and advances SYS6062 from preclinical research toward clinical evaluation. The program provides an opportunity to establish clinical proof of concept for the company’s ADC approach in advanced solid tumors, while future clinical data will be important in determining its differentiation, therapeutic potential, and suitability for specific tumor indications